Group 1 - Recent information disclosure violations have been reported by companies such as Jinsheng New Materials, *ST Aowei, and ST Nuotai, leading to significant market value loss for investors and undermining trust in the capital market's integrity [1][2] - Jinsheng New Materials received a warning letter from the Zhejiang Securities Regulatory Bureau for multiple violations, including failure to disclose related party transactions in a timely manner and mixing management with its actual controller [2] - The company has faced continuous losses, with reported revenues increasing from 243 million yuan in 2022 to 333 million yuan in 2024, but net profits showing losses of over 69 million yuan cumulatively during the same period [2] Group 2 - ST Nuotai was found to have inflated revenue by 30 million yuan through non-commercial transactions in 2021, which misled investors regarding its financial health [3][4] - The company continued to use false financial data in its convertible bond issuance documents in 2023, further misleading investors and disrupting normal financing order in the capital market [4] - Investors who purchased ST Nuotai shares between April 28, 2022, and October 23, 2024, may seek compensation for losses [4] Group 3 - *ST Aowei announced a significant downward revision of its financial forecasts, with net profit losses expected to widen from an initial estimate of 32 million to 45 million yuan to a range of 50 million to 75 million yuan [5] - The company's revenue forecast was also drastically reduced from 450 million to 520 million yuan down to 280 million to 299 million yuan [5] - Investors who bought shares between January 24, 2025, and April 21, 2025, may also pursue claims for compensation [5]

Group 1 - A new company, Wuxi Nuotai Biotechnology Co., Ltd., has been established with a registered capital of 750,000 RMB [1] - The legal representative of the company is Yu Yuxing [1] - The company's business scope includes sales of magnetic materials, research and development of new materials, manufacturing and sales of bio-based materials, and various sales of chemical products [1] Group 2 - The company is involved in the sales of medical devices, both Class I and Class II [1] - It also engages in import and export activities, including technology services, development, consulting, and promotion [1] - The company focuses on industrial enzyme preparations and bio-based material polymer technology research and development [1]

证券代码：688076 证券简称：ST 诺泰 公告编号：2025-067 江苏诺泰澳赛诺生物制药股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 9 月 5 日 （二） 股东会召开的地点：浙江省杭州市余杭区文一西路 1378 号杭州师范大学 科技园 E 座 12 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 207 | | --- | --- | | 普通股股东人数 | 207 | | 2、出席会议的股东所持有的表决权数量 | 135,496,040 | | 普通股股东所持有表决权数量 | 135,496,040 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 42.8715 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量 ...

诺泰生物 2025 年第一次临时股东会法律意见书 国浩律师（杭州）事务所 国浩律师（杭州）事务所 关 于 江苏诺泰澳赛诺生物制药股份有限公司 2025 年第一次临时股东会 法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 关 于 江苏诺泰澳赛诺生物制药股份有限公司 2025 年第一次临时股东会 法律意见书 致：江苏诺泰澳赛诺生物制药股份有限公司 国浩律师（杭州）事务所（以下简称"本所"）接受江苏诺泰澳赛诺生物制 药股份有限公司（以下简称"公司"）委托，指派律师出席公司 2025 年第一次 临时股 ...

Group 1 - The stock prices of Japan's five major trading companies have reached a 20-year high, driven by Warren Buffett's investment five years ago, creating excitement and hesitation among investors [1] - Since Buffett disclosed his investment in 2020, the average increase of the five trading companies has reached 320%, significantly outperforming the Tokyo Stock Exchange index [1] - Despite the positive market sentiment from Buffett's recent increase in Mitsubishi Corporation shares, professional institutions are expressing concerns about the current high valuation levels [1] Group 2 - The article discusses the phenomenon of market corrections during bull markets, highlighting that small adjustments do not typically trigger panic among investors [2] - Historical examples from the ChiNext index illustrate that significant declines can occur even in a bull market, leading to potential losses for investors who buy at the wrong time [2] Group 3 - The white liquor sector experienced a sharp decline following a government ban, with an average drop of over 6% in 20 trading days, while the Shanghai Composite Index saw a slight increase [3][5] - The article emphasizes that stock price performance is determined more by institutional investor behavior than by the presence of good or bad news [5][7] Group 4 - The case of Notai Bio, which saw a significant rebound after being placed under special treatment, illustrates the "bad news is good news" phenomenon, as institutional investors had already positioned themselves before the news broke [8][10] - The article suggests that understanding institutional behavior is crucial for predicting stock price movements, rather than relying solely on news events [10] Group 5 - The article concludes by advising investors to avoid blindly following prominent investors like Buffett and to focus on quantitative data rather than news [11] - Establishing a personal decision-making framework and finding suitable tools and methods are essential for navigating the information overload in the market [11]

Core Viewpoint - The company is preparing for its first extraordinary general meeting of shareholders in 2025, focusing on maintaining shareholder rights and ensuring orderly proceedings during the meeting [1][2]. Meeting Procedures - All attendees must adhere to legal obligations and meeting discipline to protect shareholder rights and maintain order [2]. - Only authorized personnel, including shareholders, directors, supervisors, and invited guests, are allowed to enter the meeting venue [2]. - Shareholders are responsible for their own expenses related to attending the meeting, and no gifts or accommodations will be provided by the company [2]. - Attendees must arrive 30 minutes before the meeting to complete registration and present identification [3]. Voting and Rights - Shareholders have the right to speak, inquire, and vote during the meeting, with specific procedures for registration and time limits for speaking [3][4]. - Voting will be conducted through both on-site and online methods, with results announced after the meeting [5]. - Shareholders must express their opinions on non-cumulative voting proposals as "agree," "disagree," or "abstain" [4]. Agenda Items - The first agenda item involves changing the accounting firm from Zhongtianyun to Zhongxi for the 2025 financial report and internal control audit, citing the need for independence after years of service from the previous firm [6][7]. - The second agenda item proposes the cancellation of the supervisory board and amendments to the company's articles of association, transferring supervisory responsibilities to the audit committee [13][14]. Company Structure Changes - The company plans to revise its articles of association to reflect the cancellation of the supervisory board and the transfer of its powers to the audit committee [14][15]. - The registered capital of the company will increase to RMB 316,051,897 following the proposed changes [16]. Communication and Compliance - The company has communicated with both the outgoing and incoming accounting firms regarding the change, ensuring all parties are aware and have no objections [12]. - The audit committee has reviewed and approved the change in accounting firms, emphasizing the qualifications and independence of the new firm [12].

Market Overview - The main funds in the Shanghai and Shenzhen markets experienced a net outflow of 69.47 billion yuan, with the Sci-Tech Innovation Board seeing a net outflow of 3.65 billion yuan [1] - A total of 251 stocks saw net inflows, while 333 stocks experienced net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 215 stocks rose, with one stock, Hangke Technology, hitting the daily limit, while 367 stocks fell [1] - The top three stocks with the highest net inflows were Yuntian Lifa (23.77 million yuan), Baijie Shenzhou (23.09 million yuan), and Daqian Energy (20.33 million yuan) [1] Continuous Fund Flow Analysis - There were 52 stocks with continuous net inflows for more than three trading days, with KHHW leading at nine consecutive days of inflow [1] - Conversely, 155 stocks had continuous net outflows, with ST Nuotai and Xuantai Pharmaceutical both experiencing 14 consecutive days of outflow [1] Top Fund Inflows - The top stocks by net inflow included: - Yuntian Lifa: 23.77 million yuan, 6.20% inflow rate, 6.38% increase [1] - Baijie Shenzhou: 23.09 million yuan, 9.56% inflow rate, 12.55% increase [1] - Daqian Energy: 20.33 million yuan, 16.32% inflow rate, 7.12% increase [1] Notable Outflows - The stock with the highest net outflow was SMIC, with a net outflow of 1.92 billion yuan and a 3.74% decrease [1] - Other significant outflows included Haiguang Information (864 million yuan) and Shijia Photon (382 million yuan) [1]

江苏诺泰澳赛诺生物制药股份有限公司 2025 年第一次临时股东会会议资料 二零二五年九月 2025 年第一次临时股东会会议资料目录 | 2025 年第一次临时股东会会议须知 | 2 | | --- | --- | | 2025 年第一次临时股东会会议议程 | 4 | | 议案一：关于变更会计师事务所的议案 | 6 | | 议案二：关于取消监事会、修订《公司章程》及其附件的议案 | 10 | | 议案三：关于制定、修订部分公司治理制度的议案 | 25 | | 附件一：江苏诺泰澳赛诺生物制药股份有限公司章程 | 26 | | 附件二：江苏诺泰澳赛诺生物制药股份有限公司股东会议事规则 | 77 | | 附件三：江苏诺泰澳赛诺生物制药股份有限公司董事会议事规则 | 91 | | 附件四：江苏诺泰澳赛诺生物制药股份有限公司累积投票制实施细则 | 100 | | 附件五：江苏诺泰澳赛诺生物制药股份有限公司关于防范控股股东、实际控制人及 | | | 其他关联方资金占用管理制度 104 | | | 附件六：江苏诺泰澳赛诺生物制药股份有限公司董事、高级管理人员薪酬管理制度 | | | 108 | | 证券代码：688076 证 ...

关于江苏诺泰澳赛诺生物制药股份有限公司 2025 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法 律法规的要求，南京证券股份有限公司（以下简称"南京证券"或"保荐机构"） 作为江苏诺泰澳赛诺生物制药股份有限公司（以下简称"诺泰生物""上市公司" 或"公司"）持续督导工作的保荐机构，负责诺泰生物上市后的持续督导工作， 并出具本持续督导跟踪报告。 南京证券股份有限公司 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作 制度，并针对具体的持续督导工作 | 保荐机构已建立并有效执行了持续督导工作 | | | 制定相应的工作计划。 | 制度，并制定了相应的工作计划。 | | | 根据中国证监会相关规定，在持续 | | | | 督导工作开始前，与上市公司或相 | 保荐机构已与诺泰生物签订保荐协议，该协 | | 2 | 关当事人签署持续督导协议，明确 | 议明确了双方在持续督导期间的权利和义 | | | 双方在持续督导期间 ...

Group 1: Company Performance - CanSino reported a revenue of 382 million yuan for the first half of 2025, a year-on-year increase of 26%, with a net loss of 13.49 million yuan, narrowing by 94.02% compared to a loss of 225 million yuan in the same period last year [1] - Wantai Bio disclosed a revenue of 844 million yuan, a year-on-year decrease of 38.25%, resulting in a net loss of 144 million yuan, indicating a shift from profit to loss due to market adjustments and government procurement impacts [2] - Jimin Health reported a revenue of 366 million yuan, a year-on-year decline of 21.30%, with a net loss of 52.70 million yuan, compared to a profit of 25.44 million yuan in the previous year [3] - ST Noratech achieved a revenue of approximately 1.048 billion yuan, a year-on-year increase of 26.07%, with a net profit of about 310 million yuan, reflecting a growth of 36.49% [5] Group 2: Market Trends and Insights - The vaccine industry is facing challenges such as intensified competition and insufficient demand, leading to performance pressure on several companies, including CanSino and Zhifei Biological [2] - Jimin Health's stock experienced a significant increase of 53.78% over a short period, indicating potential market overreaction and speculative trading [3][4] - The demand for peptide raw materials, particularly GLP-1 related products, has driven ST Noratech's performance, highlighting a strong market for specific pharmaceutical segments [5] Group 3: Shareholder Actions - TBP 3Doctors (HK) Limited plans to reduce its stake in Sanbo Brain Science by up to 6.09 million shares, representing 3% of the total share capital, which may signal a lack of confidence in the company's future prospects [6]